Oral methylxanthines for bronchiectasis

Steele, Kate; Greenstone, Michael

doi:10.1002/14651858.cd002734

Cited by 19 publications

(12 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some adults may show a favorable response with the use of anticholinergic drugs, such as ipratropium bromide [28]. Methylxanthines, such as theophylline and aminophylline are not useful in the treatment of NCFB [29]. Current evidence does not support routine use of inhaled corticosteroids in adults with NCFB [30].…”

Section: Airway Pharmacotherapymentioning

confidence: 99%

Non-cystic fibrosis bronchiectasis

Neves

Guerra

Ponce

et al. 2011

Interactive CardioVascular and Thoracic Surgery

View full text Add to dashboard Cite

Bronchiectasis is characterized by irreversible widening of the medium-sized airways, with inflammation, chronic bacterial infection and destruction of the bronchial walls. Exercise or inspiratory muscle training may improve quality of life and exercise endurance in people with non-cystic fibrosis bronchiectasis. Prolonged-use antibiotics improve clinical response rates, but may not reduce exacerbation rates or lung function. Surgery is often considered for people with extreme damage to one or two lobes of the lung who are at risk for severe infection or bleeding. In this review, the authors will focus on non-cystic fibrosis bronchiectasis, pointing out the differences in management when compared with the cystic fibrosis context, with special emphasis on surgical management.

show abstract

Section: Airway Pharmacotherapymentioning

confidence: 99%

Non-cystic fibrosis bronchiectasis

Neves

Guerra

Ponce

et al. 2011

Interactive CardioVascular and Thoracic Surgery

View full text Add to dashboard Cite

show abstract

“…Макролиды также обладают противовоспалительной активностью, однако их роль в ведении больных БЭ рассматривается в Клинической проблеме 5, касающейся АБП. Экспертами выявлены 5 систематических обзоров [56][57][58][59][60][61] побочных эффектов для иГКС и статинов совпадал с таковым для этих препаратов. В исследовании Р.Mandal et al [63] сообщается об увеличении суммарного числа побочных эффектов, которые приводили к отмене аторвастатина (по одному случаю головной боли и диареи и 2 случая сочетания головной боли и диареи).…”

Section: клинические рекомендацииunclassified

Adult patients with bronchiectasis: clinical guideline of European Respiratory Society

Редакционная¹

2018

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

“…We included 21 reviews but extracted data from, and rated the quality of, only nine reviews that reported results for people with bronchiectasis alone (Bradley 2002;Evans 2007;French 2003;Goyal 2014;Kapur 2009;Lee 2013;Wilkinson 2014;Wurzel 2011). Of the reviews with no usable data, two reviews included studies with mixed clinical populations where data were not reported separately for people with bronchiectasis (32% of participants in Pizzutto 2010 and 12% of participants in Chang 2009 had bronchiectasis only) and the remaining 10 reviews contained no any trials Franco 2003;Irons 2010;Kapur 2007;Lasserson 2001a;Lasserson 2001b;Sheikh 2001;Steele 2000;. In total, the search identified 645 references.…”

Section: Figure 2 Study Flow Diagrammentioning

confidence: 99%

“…• Four reviews on bronchodilators compared with placebo, covering short-acting beta 2 -agonists (SABA) (Franco 2003), LABA (Sheikh 2001), anticholinergics (Lasserson 2001a), and xanthines (Steele 2000). These reviews did not include any trials.…”

Section: Pharmacological Interventionsmentioning

confidence: 99%

Interventions for bronchiectasis: an overview of Cochrane systematic reviews

Welsh¹,

Spencer²,

Saba³

et al. 2013

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundBronchiectasis is a chronic respiratory disease characterised by abnormal dilatation of the bronchi, and presents typically with a chronic productive cough (or chronic wet cough in children) and recurrent infective exacerbations. It significantly impacts daily activities and quality of life, and can lead to recurrent hospitalisations, severe lung function impairment, respiratory failure and even death. ObjectivesTo provide an overview of the efficacy and safety of interventions for adults and children with bronchiectasis from Cochrane reviews.To identify gaps in the evidence base that will inform recommendations for new research and reviews, and to summarise information on reported outcomes and make recommendations for the reporting of standard outcomes in future trials and reviews. MethodsWe included Cochrane reviews of non-cystic fibrosis (CF) bronchiectasis. We searched the Cochrane Database of Systematic Reviews. The search is current to 11 February 2015. We also identified trials that were potentially eligible for, but not currently included in, published reviews to make recommendations for new Cochrane reviews. We assessed the quality of included reviews using the AMSTAR criteria. We presented an evidence synthesis of data from reviews alongside an evidence map of clinical trials and guideline data. The primary outcomes were exacerbations, lung function and quality of life. Main resultsWe included 21 reviews but extracted data from, and rated the quality of, only nine reviews that reported results for people with bronchiectasis alone. Of the reviews with no usable data, two reviews included studies with mixed clinical populations where data were not reported separately for people with bronchiectasis and 10 reviews did not contain any trials. Of the 40 studies included across the nine reviews, three (number of participants nine to 34) included children. The studies ranged from single session to year-long studies. Each review included from one to 11 trials and 28 (70%) trials in the overview included 40 or fewer participants. The total number of participants included in reviews ranged from 40 to 1040. The age range of adult participants was from 36 to 73 years and children Interventions for bronchiectasis: an overview of Cochrane systematic reviews (Review) ranged from six to 16 years. The proportion of male participants ranged from 21% to 72%. Where reported, mean baseline forced expiratory volume in one second (FEV 1 ) ranged from 1.17 L to 1.66 L and from 47% to 88% predicted. Most of the reviews had search dates older than two years.We have summarised the published evidence as outlined in Cochrane reviews, but it was not possible to draw definitive conclusions. There was inconclusive evidence on the use of long-term antibiotics and nebulised hypertonic saline for reducing exacerbation frequency and evidence that human deoxyribonuclease (RhDNase) increases exacerbation frequency. Improvements in lung function were reported for inhaled corticosteroids (ICS) though this was small and not clinically...

show abstract

Oral methylxanthines for bronchiectasis

Cited by 19 publications

References 5 publications

Non-cystic fibrosis bronchiectasis

Non-cystic fibrosis bronchiectasis

Adult patients with bronchiectasis: clinical guideline of European Respiratory Society

Interventions for bronchiectasis: an overview of Cochrane systematic reviews

Contact Info

Product

Resources

About